Deep dive on SGLT2 inhibitors with a focus on Jardiance® (empagliflozin)
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-104397 April 2021
Deep dive on DPP-4 inhibitors with a focus on Trajenta® (linagliptin)
This eLearning module and the associated videos have been commissioned and funded by Boehringer Ingelheim. The module and associated videos contain promotional content. For UK healthcare professionals.
View Trajenta® (linagliptin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-104526 July 2021
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain
Northern Ireland
PC-GB-103485 | July 2021
The importance of inhaler choice
Information intended for UK healthcare professionals only. This promotional webinar was commissioned and funded by Boehringer Ingelheim and developed in partnership with Guidelines in Practice.
View prescribing information here.
PC-GB-104812
Date of preparation: June 2021
A cancer diagnosis can be overwhelming – Macmillan’s email support can help your patients.
Your patients can sign up for regular tailored emails from Macmillan to support them through diagnosis and beyond. With information ranging from treatment to the impact of cancer on money and work, tell your patients to sign up today. Learn more here
In conversation: barriers to implementation of the NHS restructure and future opportunities
In the final In conversation video on the NHS restructure, Dr Karen Kirkham and Dr Anthony Cunliffe explore barriers to the success of the changes
In conversation: potential benefits of the NHS restructure for practice and patients
In the second In conversation video on the NHS reorganisation, Dr Karen Kirkham and Dr Anthony Cunliffe talk about the emerging benefits of the changes
In conversation: specifics and context of the NHS restructure
In the first of a new series of In conversation videos, Dr Karen Kirkham and Dr Anthony Cunliffe discuss the details and backdrop of forthcoming changes to the NHS in England
Five things you need to know about… bronchiectasis
In the first of a new series of videos, Dr Kevin Gruffydd-Jones highlights five things you need to know about bronchiectasis
NICE guidance on respiratory conditions and COVID-19: 5-minute video
Dr Kevin Gruffydd-Jones highlights important things you need to know about managing respiratory conditions in a COVID-19 context
Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13 Date of preparation: September 2021
Steglatro®▼ (Ertugliflozin)
This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting
GB-STE-00433 | June 2021
Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20 Date of preparation: July 2021
Trurapi▼ (insulin aspart 100 units/ml)
This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021
EleCare®
This formulary decision guide was developed from content provided by Abbott in a format developed by Guidelines in Practice.
UK—2100014 | Date of preparation: June 2021
Soprobec (beclometasone dipropionate) pMDI
This formulary decision guide was developed from content provided by Glenmark Pharmaceuticals Europe Ltd in a format developed by Guidelines in Practice.
View prescribing information
PP-UK-SOP-0130 V2 March 2021
PROSTAP® DCS (leuprorelin acetate)
This formulary decision guide was developed by Guidelines in Practice based on content and funding provided by Takeda UK Ltd. Information intended for healthcare professionals only.
View prescribing information here
C-APROM/UK/LEU/0075 February 2021
Nutramigen* PURAMINO*
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines inPractice.
RB-M-18261 October 2020
Nutramigen* 1, 2 & 3 LGG®
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines in Practice.
RB-M-18259 October 2020
The unrecognised epidemic of vitamin D deficiency in Black, Asian and Minority Ethnic (BAME) groups: a consensus document
Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by STADA incorporating Thornton & Ross, who provided the content.
TR-088d Date of preparation: August 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd
Improving outcomes in the management of patients with chronic coronary syndrome and stable anginal chest pain for the acute and general physician
Information intended for UK healthcare professionals only.
This promotional supplement has been commissioned and funded by A. Menarini Farmaceutica Internazionale SRL and developed in partnership with Guidelines in Practice.
View Ranexa (ranolazine) prescribing information and adverse event reporting information here
PP-RA-UK-0627
Date of preparation: July 2021
Methofill® (methotrexate) SelfDose for the treatment of adult patients with rheumatoid arthritis, Crohn’s disease, and psoriasis*
Intended for UK Healthcare professionals only.
This promotional supplement has been commissioned and funded by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
Click here for Methofill® (methotrexate) prescribing information and adverse event reporting
For full indications, please consult the summary of product characteristics.
UK-03037 | Date of preparation: May 2021
Prostap® DCS (leuprorelin acetate)—a 3-monthly gonadotrophin-releasing hormone (GnRH) agonist treatment for breast cancer
Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Takeda UK Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
C-APROM/UK/PRS/0152
Date of preparation: April 2021
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103451 Date of preparation: January 2021
Real-world usage study and survey of oral bowel cleansing for colonoscopy in Dudley, UK
This supplement has been commissioned by Norgine Pharmaceuticals Limited and contains promotional information. Information for healthcare professionals only.
Click here for PLENVU® (macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulfate anhydrous, potassium chloride, sodium chloride) Prescribing and Adverse Event Reporting.
Click here for MOVIPREP® ((macrogol 3350, sodium sulfate anhydrous, ascorbic acid, sodium ascorbate, sodium chloride, and potassium chloride) Prescribing and Adverse Event Reporting.
Click here for KLEAN-PREP (macrogol 3350, anhydrous sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) Prescribing and Adverse Event Reporting.
UK-GE-PLV-2000027
Date of preparation: February 2021
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021
Showcasing local best practice in diabetes
This Guidelines in Practice supplement aims to showcase local best practice in the diagnosis and management of diabetes. The supplement includes articles from three local initiatives that have developed their own guidance or demonstrated improvements in different areas of diabetes care:
An optimised patient pathway for the treatment of heterosexual patients with infertility
This supplement has been commissioned and funded by Merck Serono Ltd and developed in partnership with Guidelines in Practice.
Identification and management of patients with malnutrition
This supplement has been commissioned and funded by Alliance Pharmaceuticals Ltd and developed in partnership with Guidelines in Practice.
Guideline for the managed introduction of biosimilar basal insulin
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
Implementing the NICE guideline on the management of acne vulgaris
Information intended for UK healthcare professionals only.
Checklist on the implementation of the NICE guideline on atrial fibrillation: diagnosis and management
This implementation checklist has been commissioned and funded by Daiichi Sankyo UK and developed in partnership with Guidelines in Practice.
View LIXIANA (edoxaban) prescribing and adverse event reporting information
EDX/21/0535 July 2021
Implementing the NICE guidance for urinary tract infection (lower): antimicrobial prescribing for non-pregnant women without a catheter aged 16 years and over
Information intended for UK healthcare professionals only.
View prescribing information and adverse event reporting here
GB_MON_150
Date of preparation: July 2021
Implementing the Guidelines algorithm on identifying and managing allergic rhinitis in the asthma population
Information intended for healthcare professionals only.
NICE Technology Appraisal 719: Secukinumab for treating non-radiographic axial spondyloarthritis
The production of this Guidelines card has been commissioned by Novartis Pharmaceuticals UK Ltd.
View Cosentyx (secukinumab) prescribing and adverse event reporting information
MLR ID 147195 August 2021
NICE Technology Appraisal 694: Bempedoic acid▼ with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK.
View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0374 May 2021
Romosozumab▼ (Evenity®) 105mg solution for injection in prefilled pen SMC2280
The production of this Guidelines card has been commissioned by UCB Pharma Ltd.
Amgen and UCB Pharma Ltd are co-developing Evenity®.
View prescribing information and adverse event reporting
UK-P-RM-OP-2000095 December 2020
Actinic keratosis (syn. solar keratosis)—Primary Care Dermatology Society
The production, printing, and distribution of this Guidelines reprint has been commissioned and funded by Almirall Ltd. Information intended for UK healthcare professionals only.
UK-ATK-2100001 March 2021
Osteoarthritis-related pain
PP-PPF-GBR-0130 Date of preparation: June 2021
Ketan Kavia and Vishal Mashru–Sponsored symposium: Caring for the ageing patient: right drug, right patient, right time
This video has been commissioned and funded by Daiichi Sankyo and developed in partnership with Guidelines Live. Please see the bottom of the page for the full disclaimer.
EDX/21/0403 Date of preparation: May 2021